Clinical trial
ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00006369 · H. Lee Moffitt Cancer Center and Research Institute, Other · Unknown status
Key facts
| NCT number | NCT00006369 |
|---|---|
| Title | ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer |
| Official title | A Phase II, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the Treatment of Metastatic Breast Cancer in Postmenopausal Women Who Have Failed Tamoxifen Therapy |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | ERA-923 |
| Start date | Jun 1, 2000 |
| First posted | Apr 2, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: